NCT05894421 - TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 6, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2026

Conditions

Advanced Cancer

Interventions

DRUG

TQB2223 injection+ Penpulimab Injection

TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.

Trial Locations (11)

116027

NOT_YET_RECRUITING

The second hospital of Dalian medical university, Dalian

200000

RECRUITING

Tongji Hospital of Tongji University, Shanghai

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

315010

RECRUITING

The First Affiliated Hospital of Ningbo University, Ningbo

330029

RECRUITING

Jiangxi Cancer Hospital, Nanchang

350014

NOT_YET_RECRUITING

Fujian Cancer Hospital, Fuzhou

410006

RECRUITING

The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

550001

RECRUITING

Cancer Hospital of Guizhou Medical University, Guiyang

610044

RECRUITING

West China Hospital, Sichuan University, Chengdu

650118

RECRUITING

Yunnan Cancer Hospital, Kunming